rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-100-105rsp-3285Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHКлиническое значение антител к DFS70 при иммуновоспалительных ревматических заболеваниях (обзор)Clinical significance of anti-DFS70 in immunoinflammatory rheumatic diseases (review)https://orcid.org/0000-0003-1053-6952ПанафидинаТ. А.PanafidinaT. A.

Панафидина Татьяна Александровна115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

panafidina@inbox.ruhttps://orcid.org/0000-0002-4829-5210ВерижниковаЖ. Г.VerizhnikovaZh. G.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-3057-9175АвдееваА. С.AvdeevaA. S.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-5793-4689ПопковаТ. В.PopkovaT. V.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Российская Федерация, Москва, Каширское шоссе, 34а119991, Российская Федерация, Москва, ул. Трубецкая, 8, стр. 2 

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A119991, Russian Federation, Moscow, Trubetskaya str., 8, building 2 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202305032023611100105Copyright © Панафидина Т.А., Верижникова Ж.Г., Авдеева А.С., Попкова Т.В., Насонов Е.Л., 20232023Панафидина Т.А., Верижникова Ж.Г., Авдеева А.С., Попкова Т.В., Насонов Е.Л.Panafidina T.A., Verizhnikova Z.G., Avdeeva A.S., Popkova T.V., Nasonov E.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3285

Актуальность проблемы иммуновоспалительных ревматических заболеваний (ИВРЗ) для современной медицины определяется их высокой распространенностью в популяции, трудностью ранней диагностики, быстрым развитием инвалидности и неблагоприятным жизненным прогнозом. Последние данные о значимости антител к DFS70 (анти-DFS70) открыли новые возможности для оптимизации поэтапной диагностики ИВРЗ. Выявление данных антител может помочь в интерпретации положительного результата определения антинуклеарных антител (АНА) методом непрямой реакции иммунофлюоресценции на клетках HEp-2 линии при отсутствии аутоантител, специфичных для ИВРЗ. Выявление анти-DFS70 у серопозитивных по АНА пациентов без клинических и/или серологических маркеров, характерных для определенного заболевания из группы ИВРЗ, может рассматриваться в качестве потенциального маркера, исключающего данную группу заболеваний.

The relevance of the problem of immunoinflammatory rheumatic diseases (IIRD) for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and poor life prognosis. Recent data on the significance of anti-DFS70 have opened up new possibilities for optimizing the step-by-step diagnosis of IIRD. The detection of these antibodies can help in the interpretation of a positive result for antinuclear antibodies (ANA) by indirect immunofluorescence assay on HEp-2 cells (IIFA-HEp-2) in the absence of autoantibodies specific for IIRD. Detection of anti-DFS70 in antinuclear factor (ANF) seropositive patients without clinical and/or serological markers characteristic of a certain disease from the IIRD group can be considered as a potential marker that excludes this group of diseases.

иммуновоспалительные ревматические заболеванияанти-DFS70антинуклеарные антителанепрямая реакция иммунофлюоресценции на клетках HЕp-2 линииimmunoinflammatory rheumatic diseasesanti-DFS70antinuclear antibodiesindirect immunofluorescence assay on HEp-2 cellsНастоящее исследование выполнено в рамках фундаментальной темы № 1021051402790-6 «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний».ReferencesGoldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. doi: 10.1016/S0140-6736(13)61499-3Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. doi: 10.1016/S0140-6736(13)61499-3Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340-350. doi: 10.1056/NEJM200108023450506Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340-350. doi: 10.1056/NEJM200108023450506Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American college of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American college of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al.; Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren’s syndrome: A datadriven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475-487. doi: 10.1002/acr.21591Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al.; Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren’s syndrome: A datadriven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475-487. doi: 10.1002/acr.21591Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533. doi: 10.1056/NEJMoa021933Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533. doi: 10.1056/NEJMoa021933Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. doi: 10.1186/ar3258Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. doi: 10.1186/ar3258Насонов ЕЛ, Соловьев СК, Арш инов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней диагностики системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi: 10.47360/1995-4484-2021-119-128Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2021-119-128Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus – what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2020;72(5):607-614. doi: 10.1002/acr.23894Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus – what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2020;72(5):607-614. doi: 10.1002/acr.23894Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017.Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow: GEOTAR-Media;2017 (In Russ.).Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17-23. doi: 10.1136/annrheumdis-2013-203863Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17-23. doi: 10.1136/annrheumdis-2013-203863Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing guidelines. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434-444. doi: 10.1002/art.10561Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing guidelines. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434-444. doi: 10.1002/art.10561Александрова ЕН, Верижникова ЗГ, Новиков АА, Лукина ГВ. Современный взгляд на проблемы исследования антинуклеарных антител при системной красной волчанке (обзор литературы). Клиническая лабораторная диагностика. 2018;63(6):340-348. doi: 10.18821/0869-2084-2018-63-6-340-348Aleksandrova EN, Verizhnikova ZG, Novikov AA, Lukina GV. Modern look at the problems of investigation of antinuclear antibodies in systemic lupus erythematosus (literature review). Russian Clinical Laboratory Diagnostics. 2018;63(6):340-348 (In Russ.). doi: 10.18821/0869-2084-2018-63-6-340-348Kang SY, Lee WI, Kim MH, La Jeon Y. Clinical use of antiDFS70 autoantibodies. Rheumatol Int. 2019;39(8):1423-1429. doi: 10.1007/s00296-019-04299-4Kang SY, Lee WI, Kim MH, La Jeon Y. Clinical use of antiDFS70 autoantibodies. Rheumatol Int. 2019;39(8):1423-1429. doi: 10.1007/s00296-019-04299-4Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические болезни – проблемы иммунопатологии и персонифицированного лечения. Анналы Российской академии медицинских наук. 2015;70(2):169-182. doi: 10.15690/vramn.v70i2.1310Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized treatment. Annals of the Russian Academy of Medical Sciences. 2015;70(2):169-182 (In Russ.). doi: 10.15690/vramn.v70i2.1310Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of Anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne). 2018;5:88. doi: 10.3389/fmed.2018.00088Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of Anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne). 2018;5:88. doi: 10.3389/fmed.2018.00088Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: An enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front Immunol. 2015;6:116. doi: 10.3389/fimmu.2015.00116Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: An enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front Immunol. 2015;6:116. doi: 10.3389/fimmu.2015.00116Pisetsky DS. Antinuclear antibody testing – misunderstood or misbegotten? Nat Rev Rheumatol. 2017;13(8):495-502. doi: 10.1038/nrrheum.2017.74Pisetsky DS. Antinuclear antibody testing – misunderstood or misbegotten? Nat Rev Rheumatol. 2017;13(8):495-502. doi: 10.1038/nrrheum.2017.74Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. COVID-19 and immunological dysregulation: Can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502-508. doi: 10.1111/cts.12908Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. COVID-19 and immunological dysregulation: Can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502-508. doi: 10.1111/cts.12908Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095-2097. doi: 10.1007/s10067-020-05180-7Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095-2097. doi: 10.1007/s10067-020-05180-7Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-1663. doi: 10.1136/annrheumdis-2020-218009Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-1663. doi: 10.1136/annrheumdis-2020-218009Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. doi: 10.1111/cts.12953Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. doi: 10.1111/cts.12953Насонов ЕЛ, Самсонов МЮ, Лила АМ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Вестник Российской академии наук. 2022;92(7):654-660. doi: 10.31857/S086958732207012XNasonov EL, Samsonov MYu, Lila AM. Coronavirus disease 2019 (COVID-19) and autoimmunity. Annals of the Russian Academy of Sciences. 2022;92(7):654-660 (In Russ.). doi: 10.31857/S086958732207012XMahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012;2012:494356. doi: 10.1155/2012/494356Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012;2012:494356. doi: 10.1155/2012/494356Conrad K, Röber N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017;52(2):202-216. doi: 10.1007/s12016-016-8564-5Conrad K, Röber N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017;52(2):202-216. doi: 10.1007/s12016-016-8564-5Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol. 1994;151(3):587-592. doi: 10.1016/s0022-5347(17)35023-1Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol. 1994;151(3):587-592. doi: 10.1016/s0022-5347(17)35023-1Conrad K, Andrade LE, Chan EK, Mahler M, Meroni PL, Pruijn GJ, et al. From autoantibody research to standardized diagnostic assays in the management of human diseases – Report of the 12th Dresden Symposium on Autoantibodies. Lupus. 2016;25(8):787-796. doi: 10.1177/0961203316644337Conrad K, Andrade LE, Chan EK, Mahler M, Meroni PL, Pruijn GJ, et al. From autoantibody research to standardized diagnostic assays in the management of human diseases – Report of the 12th Dresden Symposium on Autoantibodies. Lupus. 2016;25(8):787-796. doi: 10.1177/0961203316644337Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889. doi: 10.1136/annrheumdis-2018-214436Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889. doi: 10.1136/annrheumdis-2018-214436Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39(11):2104-2110. doi: 10.3899/jrheum.120598Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39(11):2104-2110. doi: 10.3899/jrheum.120598Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, et al. Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods. 2016;436:50-53. doi: 10.1016/j.jim.2016.06.008Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, et al. Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods. 2016;436:50-53. doi: 10.1016/j.jim.2016.06.008Malyavantham K, Suresh L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Autoimmun Highlights. 2017;8(1):3. doi: 10.1007/s13317-017-0091-8Malyavantham K, Suresh L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Autoimmun Highlights. 2017;8(1):3. doi: 10.1007/s13317-017-0091-8Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol. 2005;32(11):2144-2149.Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol. 2005;32(11):2144-2149.Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS70kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 Pt 1):1211-1220. doi: 10.1067/mai.2000.107039Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS70kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 Pt 1):1211-1220. doi: 10.1067/mai.2000.107039Ochs RL, Mahler M, Basu A, Rios-Colon L, Sanchez TW, Andrade LE, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016;16(3):273-293. doi: 10.1007/s10238-015-0367-0Ochs RL, Mahler M, Basu A, Rios-Colon L, Sanchez TW, Andrade LE, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016;16(3):273-293. doi: 10.1007/s10238-015-0367-0Okamoto M, Ogawa Y, Watanabe A, Sugiura K, Shimomura Y, Aoki N, et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun. 2004;23(3):257-266. doi: 10.1016/j.jaut.2004.07.004Okamoto M, Ogawa Y, Watanabe A, Sugiura K, Shimomura Y, Aoki N, et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun. 2004;23(3):257-266. doi: 10.1016/j.jaut.2004.07.004Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62(1):14-26. doi: 10.1002/pros.20112Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62(1):14-26. doi: 10.1002/pros.20112Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA. Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: Many lessons learned but still many questions. Auto Immun Highlights. 2020;11(1):3. doi: 10.1186/s13317-020-0126-4Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA. Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: Many lessons learned but still many questions. Auto Immun Highlights. 2020;11(1):3. doi: 10.1186/s13317-020-0126-4Александрова ЕН, Верижникова ЖГ, Новиков АА, Панафидина ТА, Попкова ТВ. Антитела к DFS70 – новый биомаркер для исключения диагноза системной красной волчанки у АНФ-позитивных здоровых лиц. Научно-практическая ревматология. 2017;55(2 Прил 1):8.Alexandrova EN, Verizhnikova ZG, Novikov AA, Panafidina TA, Popkova TV. Antibodies to DFS70 are a new biomarker for excluding the diagnosis of systemic lupus erythematosus in ANF-positive healthy individuals. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(2 Suppl 1):8 (In Russ.).Александрова ЕН, Новиков АА, Клюквина НГ, Васильев ВИ, Лукина ГВ. Диагностическое значение моноспецифических антител к DFS70 при системных аутоиммунных ревматических заболеваниях. Медицинский алфавит. 2021(33):38-41. doi: 10.33667/2078-5631-2021-33-38-41Aleksandrova EN, Novikov AA, Klyukvina NG, Vasiliev VI, Lukina GV. Diagnostic value of monospecifc DFS70 antibodies in systemic autoimmune rheumatic diseases. Medical Alphabet. 2021(33):38-41 (In Russ.). doi: 10.33667/2078-5631-2021-33-38-41Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): What exactly are the autoantibodies trying to tell us? Arthritis Rheum. 2004;50(3):684-688. doi: 10.1002/art.20095Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): What exactly are the autoantibodies trying to tell us? Arthritis Rheum. 2004;50(3):684-688. doi: 10.1002/art.20095Miyara M, Albesa R, Charuel JL, El Amri M, Fritzler MJ, Ghillani-Dalbin P, et al. Clinical phenotypes of patients with antiDFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013;2013:703759. doi: 10.1155/2013/703759Miyara M, Albesa R, Charuel JL, El Amri M, Fritzler MJ, Ghillani-Dalbin P, et al. Clinical phenotypes of patients with antiDFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013;2013:703759. doi: 10.1155/2013/703759Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(1):191-200. doi: 10.1002/art.30084Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(1):191-200. doi: 10.1002/art.30084Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892-900. doi: 10.1002/art.20096Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892-900. doi: 10.1002/art.20096Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, et al. Autoantibodies to dense fine speckles in pediatric diseases and controls. J Rheumatol. 2015;42(12):2419-2426. doi: 10.3899/jrheum.150567Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, et al. Autoantibodies to dense fine speckles in pediatric diseases and controls. J Rheumatol. 2015;42(12):2419-2426. doi: 10.3899/jrheum.150567Peker BO, Şener AG, Tarhan EF, Kaya S. Investigation of antiDFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol. 2019;(38):3627-3633. doi: 10.1007/s10067-019-04730-yPeker BO, Şener AG, Tarhan EF, Kaya S. Investigation of antiDFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol. 2019;(38):3627-3633. doi: 10.1007/s10067-019-04730-yChoi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26(10):1051-1059. doi: 10.1177/0961203317692437Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26(10):1051-1059. doi: 10.1177/0961203317692437Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M. Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol. 2013;40(1):92-93. doi: 10.3899/jrheum.121168Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M. Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol. 2013;40(1):92-93. doi: 10.3899/jrheum.121168Infantino M, Carbone T, Manfredi M, Grossi V, Benucci M, Blank M, et al. Are anti-DFS70 autoantibodies protective? Isr Med Assoc J. 2019;21(8):509-511.Infantino M, Carbone T, Manfredi M, Grossi V, Benucci M, Blank M, et al. Are anti-DFS70 autoantibodies protective? Isr Med Assoc J. 2019;21(8):509-511.Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: What’s on the horizon? Rheumatology (Oxford). 2018;57(7):1293-1298. doi: 10.1093/rheumatology/key012Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: What’s on the horizon? Rheumatology (Oxford). 2018;57(7):1293-1298. doi: 10.1093/rheumatology/key012Aljadeff G, Shemer A, Katz I, Andrade LEC, Gilburd B, Halpert G, et al. Infusion of anti-DFS70 antibodies prolonged survival of lupus-prone mice. Lupus. 2021;30(2):320-324. doi: 10.1177/0961203320969976Aljadeff G, Shemer A, Katz I, Andrade LEC, Gilburd B, Halpert G, et al. Infusion of anti-DFS70 antibodies prolonged survival of lupus-prone mice. Lupus. 2021;30(2):320-324. doi: 10.1177/0961203320969976

The authors declare that there are no conflicts of interest present.